• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 2:34:47 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care
    Get the next $VVOS alert in real time by email
    SC 13G 1 sc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    VIVOS THERAPEUTICS, INC.

    (Name of Issuer)

     

    Common stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    92859E108

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      [  ] Rule 13d-1(b)

     

      [  ] Rule 13d-1(c)

     

      [X] Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP 92859E108

     

    1.

    Names of Reporting Persons

     

    Himmat LP

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) [  ]   (b) [  ]

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Arizona

    Number of

    Shares

    Beneficially

    Owned By

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    3,219,705 (1)

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    3,219,705 (1)

    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,219,705 (1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    17.7% (1)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1) See Item 4.

     

     
     

     

    CUSIP 92859E108

     

    1.

    Names of Reporting Persons

     

    G. Dave Singh

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) [  ] (b) [  ]

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned By

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0       

    6.

    Shared Voting Power

     

    3,219,705 (1)

    7.

    Sole Dispositive Power

     

    0       

    8.

    Shared Dispositive Power

     

    3,219,705 (1)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,219,705 (1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    17.7% (1)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1) See Item 4.

     

     
     

     

    Item 1(a). Name of Issuer

     

    Vivos Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b). Address of the Issuer’s Principal Executive Offices

     

    9137 Ridgeline Boulevard, Suite 135

    Highlands Ranch, Colorado 80129

     

    Item 2(a). Names of Persons Filing

     

    Himmat LP and G. Dave Singh (collectively, the “Reporting Persons”)

     

    Item 2(b). Address of the Principal Business Office, or if none, Residence:

     

    Himmat LP

    12 Lomita Linda

    Sandia Park, NM 87047

     

    Item 2(c). Citizenship

     

    Himmat LP is an Arizona limited partnership. G. Dave Singh is a citizen of the United States of America.

     

    Item 2(d). Title of Class of Securities

     

    Common stock, $0.0001 par value per share.

     

    Item 2(e). CUSIP Number

     

    92859E108

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

      [  ] (a) Broker or Dealer registered under Section 15 of the Exchange Act.
         
      [  ] (b) Bank as defined in Section 3(a)(b) or the Exchange Act.
         
      [  ] (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.
         
      [  ] (d) Investment company registered under Section 8 of the Investment Company Act.
         
      [  ] (e) An Investment adviser in accordance with Rule 13d-1 (b)(1)(ii)(e).
         
      [  ] (f) An employee benefit plan or endowment fund in accordance with Rule 13d 1(b)(1)(ii)(f).
         
      [  ] (g) A Parent Holding Company or control person in accordance with Rule 13d 1(b)(1)(ii)(g).

     

      [  ] (h) A Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act.
         
      [  ] (i) A Church Plan that is excluded from the definition of an investment company under Section 3 (c)(14) of the Investment Company Act.
         
      [  ] (j) Group, in accordance with Rule 13d-1 (b)(1)(ii)(j).
         
        Not applicable

     

     
     

     

    Item 4. Ownership

     

    The responses to Items 5-10 of the cover pages of this Schedule 13G are incorporated herein by reference.

     

    As of December 31, 2020, each of G. Dave Singh and Himmat LP may be deemed to beneficially own 3,219,705 shares of the Issuer’s common stock, representing 17.7% of the total shares of common stock issued and outstanding.

     

    The percentages of the shares of common stock held by the Reporting Persons are based on 18,191,675 shares of common stock issued and outstanding as of December 14, 2020 as reported in the Issuer’s prospectus (File No. 333-249412) filed with the Securities and Exchange Commission on December 14, 2020.

     

    Himmat LP is the record holder of 3,219,705 shares of common stock. G. Dave Singh is a member and manager of Himmat LP and has voting and investment discretion with respect to the common stock held of record by Himmat LP. As such, G. Dave Singh may be deemed to have beneficial ownership of the securities held of record by Himmat LP.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not Applicable

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable

     

    Item 10. Certification

     

    Not Applicable

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 16, 2021

     

      Himmat LP
         
      By: /s/ G. Dave Singh
      Name: G. Dave Singh
      Title: Member and Manager

     

      /s/ G. Dave Singh
      G. Dave Singh

     

     

     

    Get the next $VVOS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VVOS

    DatePrice TargetRatingAnalyst
    8/13/2021$11.00 → $10.00Buy
    Roth Capital
    More analyst ratings

    $VVOS
    SEC Filings

    View All

    Vivos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

    9/17/25 8:41:12 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

    9/12/25 4:52:50 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Vivos Therapeutics Inc.

    424B5 - Vivos Therapeutics, Inc. (0001716166) (Filer)

    9/12/25 4:50:44 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment

    LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced first time, peer-reviewed published data confirming that the Vivos DNA (Daytime-Nighttime Appliance®) is both safe and efficacious in treating children suffering from OSA. Results from a multicenter clinical trial, now published in the European Journal of Pediatrics, represent a significant milestone in the fight against one of the m

    9/17/25 8:30:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

    Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today reported

    8/19/25 4:20:00 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call

    LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today announced it plans to release its second quarter 2025 financial results after market close today, Tuesday, August 19, 2025. The Company will conduct a conference call at 5:00 pm (Eastern Time) on August 19, 2025, to review the results and provide an overview of the C

    8/19/25 8:30:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Skaff Michael C claimed ownership of 1,342,498 shares (SEC Form 3)

    3 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

    6/20/25 5:54:04 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Huntsman Ronald Kirk

    4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

    11/27/24 4:47:13 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Amman Bradford K.

    4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

    11/27/24 4:43:54 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Vivos Therapeutics with a new price target

    Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $10.00 from $11.00 previously

    8/13/21 1:08:07 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Roth Capital reiterated coverage on Vivos Therapeutics with a new price target

    Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $11.00 from $12.00 previously

    5/18/21 10:44:01 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Leadership Updates

    Live Leadership Updates

    View All

    Vivos Therapeutics Adds to Management Team to Support Expansion and Growth

    LITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company"), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced the appointments of Michael (Mike) E. Bruhn as its Executive Vice President of Business Operations Integration, and Dr. Terry Jones as its new Senior Vice President of Human Resources. These hires demonstrate Vivos' commitment to the successful implementation and expansion of its new sleep testing center and direct patient treatment operations, highlighted by Vivos' recent acquisition of The Sleep Center of Nevada and Vivos' ongoing, active e

    7/30/25 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Financials

    Live finance-specific insights

    View All

    Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

    Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today reported

    8/19/25 4:20:00 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call

    LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today announced it plans to release its second quarter 2025 financial results after market close today, Tuesday, August 19, 2025. The Company will conduct a conference call at 5:00 pm (Eastern Time) on August 19, 2025, to review the results and provide an overview of the C

    8/19/25 8:30:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada

    Transaction brings OSA diagnostic revenue to Vivos, plus Vivos' highly effective OSA treatment options to thousands of potential patients in the greater Las Vegas area Transaction also completes Vivos' business model pivot to target high patient volume centers and higher margin revenues Over $11 million in new financing secured by Vivos, including a senior secured loan from Streeterville Capital and an equity private placement by existing investor New Seneca Partners LITTLETON, Colo., June 11, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leader in delivering and promoting sleep wellness and health through its proprietary, non-invas

    6/11/25 8:30:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

    SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

    11/14/24 4:49:30 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

    SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

    11/14/24 4:05:24 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Vivos Therapeutics Inc.

    SC 13G - Vivos Therapeutics, Inc. (0001716166) (Subject)

    9/24/24 2:59:09 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care